Clinical trials: Infections, Coronavirus
COVID-19, Symptoms and Signs
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
The goal of this clinical trial is to examine the effectiveness of intranasal-administered Chlorpheniramine Maleate in COVID-19-positive participants as part of early treatment for COVID-19.
- Conditions
- COVID-19, Symptoms and Signs, COVID-19 Pandemic, Coronavirus Disease 2019
- Trial name
- ACCROS-III (NCT05886829)
- Testing
- Chlorpheniramine Maleate 0.4% Nasal Spray
- Where
- Honduras
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
Corona Virus Infection
Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia
This is a phase I/II clinical trial using adoptive cell therapy with NK cells or memory T cells in patients affected by COVID-19.
- Trial name
- RELEASE (NCT04578210)
- Testing
- T memory cells and NK cells
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Coronavirus Infection, Orthopedic Disorder
Retrospective Case Series of COVID19+ Patients Undergoing Orthopedic Surgery
Over the last months, the Rizzoli Orthopedic Institute in Bologna, Italy, has drained orthopedic urgencies from all other hospitals in the urban and suburban area.
- Conditions
- Coronavirus Infection, Orthopedic Disorder, Bone Fracture, Bone Metastases
- Trial name
- COVID19&SURG (NCT05881343)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Ortopedico Rizzoli
Coronavirus, COVID
ACCESS A Master Digital Surveillance Protocol for COVID-19
ACCESS enables individuals to contribute to critical research, via an iOS and Android smartphone mobile application. ACCESS combines patient reported outcomes, data from wearable devices and real-world data (such as claims, EHRs…
- Conditions
- Coronavirus, COVID, COVID-19, COVID19
- Trial name
- ACCESS (NCT04363268)
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Medable Inc.
COVID, Sars-CoV2
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection
- Trial name
- NCT04445207
- Testing
- Convalescent Plasma
- Where
- United States
- Sponsor
- Jonathan Gerber
Coronavirus
COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)
Since the start of this epidemic, numerous clinical and fundamental studies have been conducted to best adapt the individual management of COVID-19 cases [1-6].
- Trial name
- AntiCoV-HB (NCT04416308)
- Testing
- NG test, Blood test, Self-questionnary
- Where
- 9 sites in France
- Volunteers
- 9,453 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Long COVID
VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)
This study aims to evaluate the effectiveness of VSL#3® in reducing Fatigue and other symptoms in Long Covid Syndrome compared to placebo.
- Trial name
- DELong#3 (NCT05874089)
- Testing
- VSL#3®
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Coronavirus Infections, Gut Microbiome
The Association of Gut Microbiota With COVID 19 Infection in Children
Although COVID-19 infects gastrointestinal tissues, little is known about the roles of gut commensal microbes in susceptibility to and severity of infection.
- Conditions
- Coronavirus Infections, Gut Microbiome, Childhood ALL
- Trial name
- NCT05303155
- Testing
- 16S rRNA sequencing
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hallym University Kangnam Sacred Heart Hospital
COVID-19
Mechanisms Underlying Long-term Fatigue and Exercise Intolerance Following COVID-19
The MEXICO study is an observational study that aims to identify underlying mechanisms contributing to exercise intolerance in the presence of persistent COVID-19 symptoms (Long COVID).
- Trial name
- MEXICO (NCT04914754)
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- University College, London
Virus Diseases
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases.
- Trial name
- COVIMAR (NCT04710199)
- Testing
- Maraviroc experimental group, Standard treatment
- Where
- 2 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Coronavirus Infections
Prospective Monitoring of BNT162b2 Second Vaccination Booster Effects in Health Care Workers (HCW)
The SARS-CoV-2 virus causes severe respiratory illness and is an ongoing global pandemic. On December 12, 2020 the FDA approved Pfizer's BioNTech vaccine BNT162b2 which is a messenger RNA type of vaccine for use.
- Trial name
- NCT05516459
- Testing
- Pfizer BNT162b2 Vaccine
- Where
- Israel
- Volunteers
- 635 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Covid19
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability…
- Trial name
- COMET-PEAK (NCT04779879)
- Testing
- Sotrovimab (Gen1), Sotrovimab (Gen2)
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 354 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19
Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.
The Coronavirus SARS CoV-2 (COVID-19) pandemic is causing a major global health crisis that is disrupting our hospital organizations and creating potential infectious risks for hospital staff on the front line when it comes to…
- Trial name
- PERSO-COVID (NCT04488484)
- Testing
- Serology test follow-up
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (3~17 years old) Research purpose:Main purpose:To evaluate the safety and tolerability of recombinant New Coronavirus vaccine (CHO cells) in…
- Trial name
- NCT04961359
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Coronavirus, Iatrogenic Disease
Adverse Events Related to Treatments Used Against Coronavirus Disease 2019
The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020.
- Conditions
- Coronavirus, Iatrogenic Disease, Acute Kidney Injury, ARDS, Human
- Trial name
- CovidTox (NCT04314817)
- Testing
- Any drug used to treat Covid-19
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Vitamin C, COVID-19
Lessening Organ Dysfunction With VITamin C - COVID-19
LOVIT-COVID is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at…
- Conditions
- Vitamin C, COVID-19, Hospitalized Patients
- Trial name
- LOVIT-COVID (NCT04401150)
- Testing
- Vitamin C, Control
- Where
- 2 sites in Canada
- Volunteers
- 392 people
- Sponsor
- Université de Sherbrooke
Covid19
Evaluating the Impact of EnteraGam In People With COVID-19
Background: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged as a potentially life-threatening disease in Wuhan, China, at the end of 2019.
- Trial name
- PICNIC (NCT04682041)
- Testing
- Bovine Plasma-Derived Immunoglobulin Concentrate, Standard of care
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Entera Health, Inc
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Antigen Rapid Diagnostic Tests for Community Identification of Severe Acute Respiratory Syndrome Coronavirus 2
Background: Background: Testing with antigen-detecting rapid diagnostic tests (Ag-RDTs), including in asymptomatic individuals, has the potential to promptly identify more Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT05458557
- Testing
- Rapid Antigen Testing
- Where
- Kenya
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
COVID-19 Testing, CNS Disease
Determination of COVID-19 Related Virus in Central Nervous System
Coronavirus disease 2019 (COVID-19) is a highly infectious pandemic disease caused by SARS-CoV-2 virus. Central Nervous System (CNS) complications associated with COVID-19 might be secondary sequelae due to exuberant systemic…
- Conditions
- COVID-19 Testing, CNS Disease, CNS Infection
- Trial name
- NCT04775784
- Testing
- Determination of SARS-CoV2 presence in CNS
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- IRCCS San Raffaele
Coronavirus
Dexamethasone and COVID-19 Inpatient Mortality
The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and…
- Trial name
- NCT04926571
- Testing
- Dexamethasone Oral
- Where
- United States
- Volunteers
- 14,105 people
- Sponsor
- Aetion, Inc.